Loading...
•
Mar 31, 2020
Atara Q1 2020 Earnings Report
Atara Biotherapeutics reported financial results and operational progress for Q1 2020.
Key Takeaways
Atara Biotherapeutics reported a net loss of $73.5 million, or $1.20 per share, for the first quarter of 2020. The company's cash, cash equivalents, and short-term investments totaled $214.6 million as of March 31, 2020, which is expected to fund operations into the second quarter of 2021.
Atara remains on track to initiate a tab-cel® BLA submission for patients with EBV+ PTLD in the second half of 2020.
Atara expects to present ATA188 Phase 1a six-month clinical results for the dose-escalating cohorts 1-4 and 12-month results for cohorts 1-3 in Q2 2020.
Atara has temporarily paused the screening and enrollment of patients in the Phase 1b randomized placebo-controlled study to ensure sites can focus on meeting the needs of patients with COVID-19.
Atara believes that its cash, cash equivalents and short-term investments as of March 31, 2020, are sufficient to fund planned operations into the second quarter of 2021.
Atara
Atara
Forward Guidance
Atara believes that its cash, cash equivalents and short-term investments as of March 31, 2020, are sufficient to fund planned operations into the second quarter of 2021.